Question · Q4 2025
Leigh asked about XIIDRA's performance expectations for 2026, specifically if mid-single-digit sales growth is anticipated, with price improvement offsetting volume decline. She also questioned the confidence in achieving the 23% EBITDA margin target by 2028 (200 basis points per year) and whether margin improvement will occur in equal steps.
Answer
Chairman and CEO Brent Saunders and President of Global Pharmaceuticals and International Consumer Andrew Stewart confirmed expectations for mid-single-digit growth for XIIDRA in 2026, driven by higher revenue growth from better net pricing (gross-to-nets moving from mid-70s to low-70s), despite slower TRx growth. CFO Sam Eldessouky provided further details on the net pricing benefit. Brent Saunders expressed high confidence in the 2028 EBITDA margin target, citing Q4 2025's 17.5% margin as a strong start and emphasizing company-wide focus and disciplined project teams for margin improvement.
Ask follow-up questions
Fintool can predict
BLCO's earnings beat/miss a week before the call